India’s largest actively managed equity fund, PPFAS Flexi Cap, is increasing exposure to beaten-down IT stocks, taking a contrarian view on...

Digital infrastructure firm ITG is aiming for a valuation of up to $2.67 billion in its US stock market debut, seeking to raise as much as ...

Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...

IT stocks rebounded after a sharp sell-off triggered by Accenture’s guidance cut, with gains led by Coforge and Tech Mahindra. Analysts see...

SpaceX shares surged early on Tuesday as investors bet on Elon Musk's sprawling empire that spans rockets to AI, even though the stock carr...

Trump's investment accounts saw thousands of trades totaling hundreds of millions of dollars between January and March. This feverish activ...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

Electronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...

India's Chief Economic Advisor V Anantha Nageswaran warns that artificial intelligence stock valuations are a bubble. He believes the narra...

A new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

SpaceX has priced its record-breaking U.S. IPO at $135 per share, raising $75 billion and valuing the company at $1.77 trillion. This makes...

U.S. stocks largely rose Monday, with the Nasdaq and chipmakers leading the gains as investors sought bargains after Friday's selloff. Reli...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...